Close menu




January 20th, 2022 | 09:15 CET

Valneva, XPhyto, BioNTech - This is the breakthrough

  • Biotechnology
Photo credits: pixabay.com

The shares of vaccine manufacturers are currently experiencing a rollercoaster ride. While BioNTech, Pfizer and Moderna vaccines, based on mRNA technology, continue to reduce their incredible stock market valuation, Valneva, the manufacturer of an inactivated vaccine, has made a brilliant comeback on the stock market floor. The reasons for the good mood were positive data regarding the neutralization of the Omicron variant, which pushed the share up by more than 30% after trading hours.

time to read: 3 minutes | Author: Stefan Feulner
ISIN: VALNEVA SE EO -_15 | FR0004056851 , MODERNA INC. DL-_0001 | US60770K1079 , BIONTECH SE SPON. ADRS 1 | US09075V1026

Table of contents:


    Valneva - Blow after blow

    As recently as the afternoon, French-Austrian vaccine maker Valneva was seeking damage control as the Company's share price plunged about 50% since the start of the year to a low of EUR 12.68. "The process is progressing as planned, and we currently see no reason to question our previously communicated guidance of a possible first EMA approval in the first quarter," the Company said on Wednesday in response to a request from news agency Reuters.

    However, a short time later came the redemptive news, marking a milestone in the Company's young history. Preliminary laboratory studies show that three doses of Valneva's inactivated COVID-19 vaccine candidate VLA2001 neutralize the Omicron variant (B.1.1.529 line), a company statement said. 100% of serum samples tested showed neutralizing antibodies to the original virus and the Delta variant and 87% to the Omicron variant.

    Dr. Juan Carlos Jaramillo, Chief Medical Officer of Valneva, commented, "We are very pleased with these results, confirming the potential of our inactivated adjuvanted whole virus vaccine for broad-spectrum protection and its ability to combat the currently circulating variants of concern. Furthermore, Valneva expects to submit all applications to the respective authorities in time to receive a potential approval still in the first quarter.

    In November, the vaccine producer announced that the European Commission had signed an agreement with the Company to supply up to 60 million doses of VLA2001 over a two-year period - including 24.3 million doses in 2022. Delivery of the vaccine in Europe is currently expected in April 2022, subject to EMA approval. In December 2021, Valneva also announced that it had signed an agreement to supply one million doses of VLA2001 to the Kingdom of Bahrain, subject to approval by the Bahrain Health Authority, in the first quarter of 2022. Now Valneva could become a "top dog" after all, as a recent analysis at researchanalyst.com suggested.

    XPhyto - Expansion ahead

    Also progressing well is life sciences accelerator XPhyto, which specializes in investing in next-generation drug delivery, diagnostics, and new active pharmaceutical ingredients. These include precision transdermal and orally dissolvable drug formulations, rapid and cost-effective testing for infectious diseases and oral health, and standardization of new pharmaceutical agents for neurological applications, including psychedelic compounds and cannabinoids. The Company has research and development sites in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.

    In addition to the appointment of Drahoslav Zdarek as the new Head of Sales, the Company's top priority is the commercialization of Covid-ID Lab. The Company's CE Mark-approved RT-PCR rapid test in Germany is registered as a commercial in vitro diagnostic test (CE-IVD) in the European Union.

    A distribution agreement was signed with TechUnit to distribute Covid-ID Lab in the Czech Republic as an initial priority market, followed by Hungary, Slovakia, Ukraine and Russia. "The signing of the distribution agreement with TechUnit is an important step in building a strong European sales market," said Prof. Dr. Thomas Beckert. "This is an important relationship with excellent potential for further territorial expansion."

    You can read a detailed report on XPhyto here. The Company will also present at the second International Investment Forum on February 17, 2022. Free registration is available at www.ii-forum.com.

    BioNTech continues in free fall

    While Valneva is bullish after reporting positive data, the "traditional" vaccine producers continue to lose ground. Moderna, for example, lost around 6%, while BioNTech is down 2.5% at USD 165.41. The next support area is around USD 150. If this level falls, the next broad support area would be around USD 132.


    Valneva could celebrate a liberation blow after the sell-off of the last days with the published data. On the other hand, from a technical point of view, the lights continue to be red for the mRNA manufacturers BioNTech and Moderna. The path of XPhyto continues and points to growth through the market launch in new countries.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Nico Popp on February 2nd, 2023 | 18:04 CET

    Bulging pipeline at BioNTech, Cardiol Therapeutics - what is the problem at Aurora Cannabis?

    • Biotechnology
    • Cannabis
    • Cancer

    He who heals is right. It is not quite that simple with active ingredients that are about to be approved. Drugs and vaccines must undergo extensive studies and, last but not least, have to prevail against the existing competition. We look at the pipelines of three hot stocks and venture a forecast: Where is the greatest potential for investors?

    Read

    Commented by Stefan Feulner on February 1st, 2023 | 20:29 CET

    BioNTech, Defence Therapeutics, PAION - All dams broken

    • Biotechnology

    High price fluctuations due to approvals or successful test results are more the norm than the rule in the biotechnology sector. It is common for smaller stocks, in particular, to multiply within a few days. For example, the shares of Ambrx Biopharma increased by a whopping 1,000% within just one day, while the German biotech hopeful PAION doubled in price within a week. The next candidates for above-average performances are already waiting in the wings.

    Read

    Commented by André Will-Laudien on January 30th, 2023 | 09:13 CET

    Mega biotech rally 2023! Defence Therapeutics, Bayer, BioNTech, Morphosys - Where to put the money?

    • Biotechnology
    • Cancer
    • Covid19
    • Investments

    Who would have thought it? Since the beginning of the year, the stock markets have been jubilant despite difficult predictions about the economic trend in 2023. High inflation and rising interest rates are not a good breeding ground for the popular biotech stocks because they have to constantly refinance their research expenses. As the risk fee is readjusted as costs rise, investors demand higher premiums for providing money. However, some biotech stocks have taken off since the beginning of the year despite adverse conditions. What is their secret?

    Read